Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats
Related Experiment Video
Updated: Aug 9, 2026
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
Guangming Li1, Qing Xie, Yi Shi
1Department of Gastroenterology, Xinhua Hospital, Shanghai Second Medical University, Shanghai 200092, China.
Background:
Connective tissue growth factor (CTGF) is a highly profibrogenic molecule implicated in hepatic fibrogenesis. Small interfering RNA (siRNA) is an effective tool to silence gene expression post-transcriptionally. Therefore, we conducted an investigation to determine if intraportal vein siRNA injection targeting CTGF inhibits CTGF expression on rat liver in vivo and furthermore whether it protects the liver from liver fibrosis.
Methods:
Some rats received carbon tetrachloride (CCl4) by subcutaneous injections every three days for six consecutive weeks, and meantime they also obtained either siRNA (0.1 mg/kg) targeting CTGF, saline or a control siRNA by intraportal vein injection to rats' liver at the same pattern. Other rats received CCl4 by subcutaneous injection for 2 weeks, followed by CCl4 and CTGF siRNA intraportal vein injection for four more weeks.
Results:
Intraportal vein injection of CTGF siRNA specifically reduced the expression of CTGF protein in rat liver, and these effects were maintained for 3 days. Six weeks after CCl4 injection, prominent upregulations were observed in the gene expressions of CTGF, type I, III collagen, laminin, tissue inhibitor metal proteinase-1 (TIMP-1) and transforming growth factor-beta1 (TGF-beta1) in saline or control siRNA-treated rats livers. Administrating CTGF siRNA for 4 or 6 weeks, by contrast, markedly attenuated the induction of CTGF, type I, III collagen, laminin, TIMP-1 and TGF-beta1 genes, whereas Smad2, 7 gene expression was not affected. The number of active hepatic stellate cells (HSCs) determined by the expression of alpha-smooth muscle actin was also significantly decreased. The CTGF siRNA treatment markedly reduced serum procollagen type III, hepatic hydroxyproline and liver fibrosis staging.
Conclusions:
Silencing CTGF expression with siRNA demonstrates therapeutic potential to prevent liver fibrosis by inhibiting HSC activation with consequent extracellular matrix accumulation and the upregulation of TGF-beta1 gene expression.
Insights
Targeting connective tissue growth factor (CTGF) with small interfering RNA (siRNA) effectively reduced liver fibrosis in rats. This approach inhibited hepatic stellate cell activation and extracellular matrix accumulation, showing therapeutic potential.
Area of Science:
- Hepatology
- Molecular Biology
- RNA Interference Therapeutics
Background:
- Connective tissue growth factor (CTGF) is a key driver of liver fibrosis.
- Small interfering RNA (siRNA) offers a method for targeted gene silencing.
- Investigating CTGF siRNA's efficacy in preventing liver fibrosis is crucial.
Purpose of the Study:
- To assess if intraportal CTGF siRNA injection inhibits CTGF expression in rat livers.
- To determine if CTGF siRNA protects against carbon tetrachloride-induced liver fibrosis.
- To evaluate the impact of CTGF siRNA on fibrotic markers and cellular activation.
Main Methods:
- Rats were treated with carbon tetrachloride (CCl4) and received intraportal injections of CTGF siRNA, control siRNA, or saline.
- CTGF siRNA was administered either concurrently with CCl4 or after an initial CCl4 treatment period.
- Gene and protein expression of fibrotic markers, hepatic stellate cell (HSC) activation, and fibrosis staging were analyzed.
Main Results:
- Intraportal CTGF siRNA significantly reduced CTGF protein expression in rat livers.
- CTGF siRNA administration attenuated the upregulation of CTGF, collagen, laminin, TIMP-1, and TGF-beta1 genes induced by CCl4.
- CTGF siRNA treatment decreased active HSCs, serum procollagen type III, hepatic hydroxyproline, and overall liver fibrosis staging.
Conclusions:
- Silencing CTGF with siRNA is a promising therapeutic strategy for liver fibrosis.
- CTGF siRNA inhibits HSC activation and subsequent extracellular matrix accumulation.
- This approach effectively reduces TGF-beta1 gene expression, a key fibrogenic mediator.
Related Concept Videos
01:24Cirrhosis II: Pathophysiology
01:23Cirrhosis I: Introduction
01:24Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...